Prof. Lidija Kandolf Sekulović

Department of Dermatology
EADO Board Member
MWS Board Member
Faculty of medicine, Military Medical Academy
University of Defence
17 Crnotravska, Belgrade, Serbia
Phone/Fax +381113608583

e-mail: <u>lkandolfsekulovic@gmail.com</u>

Lidija Kandolf Sekulović MD, PhD, is Deputy Head of the Department of Dermatology, Faculty of Medicine, Military Medical Academy, Vice President and founder of the Central and South-East European Melanoma Group (CSEEMEG), and Serbian Melanoma Group secretary. Also, she served from 2015-2019 as a national coordinatior of Euromelanoma campaign in Serbia. Within CSEEMEG, she worked on regional cooperation and development of clinical melanoma registries in member countries as a part of European Melanoma registry. Within Serbian Melanoma Group, national melanoma diagnosis and treatment guidelines in 2014 and 2019 were published.

She is a Board member of the European Association for Dermatologic Oncology (EADO), Melanoma World Society (MWS), European Dermatology Forum (EDF), International Dermoscopy Society (IDS), and active member of EORTC Melanoma group, EADV, ESMO and ASCO.

She was born in Belgrade, graduated in 1996, finished specialization in dermatovenerology in 1999, postgraduate studies in immunology in 2001, PhD in dermatologic oncology in 2007 and subspecialization in oncology in 2013. From 2017, she is a full professor of dermatovenerology at Medical Faculty, Military Medical Academy, Belgrade, Serbia. She has published 2 textbooks, 15 book chapters, 45 in extenso and more than 100 abstracts in peer-reviewed journals, and symposia proceedings. She is an invited presenter of several regional and international meetings. Her current research is focused on gene alterations in skin cancer, including the research on familial melanoma, circulating tumor DNA, gene alterations in metastatic melanoma and research on sentinel lymph node status in patients with melanoma. Also, since 2015 as a coordinator of the EADO project "Access to innovative medicines for metastatic melanoma" she conducted several European and global surveys on access to first-line recommended treatments for melanoma and other skin cancers that revealed large disparities within Europe and worldwide.